Durect (NASDAQ:DRRX) Bolsa

Durect

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.

Durect Corp

Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), including a novel <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">therapeutic molecule, larsucosterol</a>.
Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.
Alcoholic hepatitis is&nbsp;a severe liver inflammation caused by excessive alcohol consumption.&nbsp;It is characterized by the rapid onset of jaundice and liver enlargement.
Bausch Health&#8217;s hepatology development and commercial capabilities are well-suited to support the clinical development and potential commercialization of larsucosterol.
The companies add that there is currently no Food and Drug Administration- or European Medicines Agency-approved treatment for AH.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90" target="_blank" rel="noreferrer noopener">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a>
Bausch Health will pay $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million, with the potential for two additional net sales milestone payments of up to $350 million.
A registrational Phase 3 program to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH is being planned.
The trial will be a randomized, double-blind, placebo-controlled, multi-center study. The primary endpoint will be 90-day survival.
The trial design will incorporate feedback received from the FDA during a Type B meeting under Breakthrough Therapy Designation and learnings from the prior Phase 2b AHFIRM trial in AH.
The acquisition of the clinical development program for larsucosterol in AH complements the ongoing Bausch Health RED-C clinical program, which is designed to assess the efficacy of a next-generation therapeutic, rifaximin SSD, to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization and all-cause mortality.
Patient enrollment in two global Phase 3 studies is now complete with efficacy and safety results expected to be announced in early 2026.
The transaction is expected to close in the third quarter of 2025.
Last year, Bausch Health <a href="https://www.benzinga.com/news/large-cap/24/10/41313679/bausch-lomb-sale-process-gains-momentum-as-tpg-and-blackstone-join-forces" target="_blank" rel="noreferrer noopener">was in talks with several</a> private equity firms about selling Bausch + Lomb Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>).
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40884021/contact-lens-supplier-bausch-lomb-eyes-sale-amid-separation-challenges-as-parent-bausch-health-fac" rel="noreferrer noopener">of which is due by 2027</a>.
BHC, DRRX Price Actions: Bausch Health stock is down 0.36% at $6.87, and DURECT stock is up 238.34% at $1.87 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46688163/unitedhealth-misses-q2-mark-but-vows-a-healthier-2026" target="_blank" rel="noreferrer noopener">UnitedHealth Misses Q2 Mark But Vows A Healthier 2026</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

BLCO

DRRX

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

<h3>Gainers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) stock moved upwards by 238.3% to $1.87 during Tuesday's regular session. The market value of their outstanding shares is at $17.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares increased by 59.3% to $1.18. The market value of their outstanding shares is at $1.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares rose 29.03% to $0.71. The company's market cap stands at $18.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares rose 25.74% to $0.69. The market value of their outstanding shares is at $16.6 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares increased by 19.73% to $16.59. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares rose 16.91% to $8.64. The company's market cap stands at $161.5 million. As per the news, the Q2 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares fell 53.8% to $3.33 during Tuesday's regular session. The company's market cap stands at $5.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 26.05% to $3.35. The market value of their outstanding shares is at $10.7 million. The company's, Q2 earnings came out yesterday. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) shares declined by 24.77% to $4.86. The market value of their outstanding shares is at $831.3 million. As per the press release, Q2 earnings came out today. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 21.96% to $0.35. The company's market cap stands at $18.4 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares decreased by 21.42% to $3.18. The market value of their outstanding shares is at $25.3 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAKA#NASDAQ">NAKA</a>) shares declined by 21.35% to $8.33. The company's market cap stands at $80.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDI

EKSO

MBRX

NAKA

PRPH

SLRX

SONN

SRPT

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.
The Dow traded down 0.40% to 44,658.06 while the NASDAQ fell 0.22% to 21,131.59. The S&amp;P 500 also fell, dropping, 0.20% to 6,376.82.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Real estate shares jumped by 1.5% on Tuesday.
In trading on Tuesday, industrials stocks dipped by 1.2%.
Top Headline
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported downbeat second-quarter 2025 earnings on Tuesday and reestablished its 2025 guidance.
The insurance giant reported adjusted earnings of $4.08, down from $6.80 a year ago, missing the consensus of $4.95. Revenues increased 13% year over year to $111.62 billion, missing the consensus of $111.69 billion.
UnitedHealth reestablished its fiscal year 2025 guidance, with adjusted earnings of at least $16 per share versus a consensus of $22.33 and sales guidance of $445.5 billion-$448 billion compared to the analyst estimate of $449.5 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares shot up 271% to $2.0498 after Bausch Health announced plans to acquire the company.</li>
<li>Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) got a boost, surging 25% to $17.27 after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares were also up, gaining 102% to $1.35 after the company announced it will offer its technology through the TIPS contract it entered with Creeksource Consulting.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares dropped 54% to $3.3169 after the company announced a $8 million public offering consisting of shares as well as class E and F warrants.</li>
<li>Shares of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) were down 21% to $54.34 after the company lowered its 2025 sales outlook, citing reduced growth expectations for Wegovy and Ozempic in the US and weaker Wegovy penetration.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 42% to $0.0487 after the company announced a 250-to-1 share consolidation.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $67.55 while gold traded up 0.5% at $3,326.10.
Silver traded up 0.2% to $38.28 on Tuesday, while copper rose 0.4% to $5.6395.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.46%, while Spain's IBEX 35 Index gained 0.91%. London's FTSE 100 rose 0.80%, Germany's DAX 40 gained 1.15% and France's CAC 40 rose 0.87% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.79%, Hong Kong's Hang Seng falling 0.15%, China's Shanghai Composite rising 0.33% and India's BSE Sensex gaining 0.55%.
Economics
<ul class="wp-block-list">
<li>The number of job openings declined by 275,000 to 7.437 million in June, compared to market expectations of 7.55 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 2.8% year-over-year for May.</li>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $907.7 billion in June.</li>
<li>The U.S. trade deficit in goods shrank by $10.4 billion to $86 billion in June.</li>
<li>The Dallas Fed&#8217;s general business activity index rose 6.4 points to a reading of 2 in July.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

STAI

WLGS

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views

WIIM

DURECT shares are trading higher after announcing that Bausch Health will acquire the company for $63 million.

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.4% on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.02% to 44,828.67 while the NASDAQ rose 0.41% to 21,264.97. The S&amp;P 500 also rose, gaining, 0.18% to 6,401.25.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Information technology shares jumped by 0.9% on Tuesday.
In trading on Tuesday, health care stocks dipped by 1.2%.
Top Headline
The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) reported better-than-expected earnings for the second quarter on Tuesday.
The company posted quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.42 per share. The company reported quarterly sales of $20.889 billion which beat the analyst consensus estimate of $20.765 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares shot up 360% to $2.54 after Bausch Health announced plans to acquire the company.</li>
<li>Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) got a boost, surging 156% to $1.90. the company announced it has been granted an extension to meet Nasdaq&#8217;s equity and bid price standards.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares were also up, gaining 79% to $1.1999 after the company announced it will offer its technology through the TIPS contract it entered with Creeksource Consulting.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares dropped 56% to $3.19 after the company announced a $8 million public offering consisting of shares as well as class E and F warrants.</li>
<li>Shares of Profusa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFSA#NASDAQ">PFSA</a>) were down 51% to $0.9501.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 44% to $0.0471 after the company announced a 250-to-1 share consolidation.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $67.55 while gold traded up 0.2% at $3,314.90.
Silver traded up 0.1% to $38.230 on Tuesday, while copper rose 0.6% to $5.6510.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.6%, while Spain's IBEX 35 Index gained 1.1%. London's FTSE 100 rose 0.9%, Germany's DAX 40 gained 1.2% and France's CAC 40 rose 1.1% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.79%, Hong Kong's Hang Seng falling 0.15%, China's Shanghai Composite rising 0.33% and India's BSE Sensex gaining 0.55%.
Economics
<ul class="wp-block-list">
<li>The number of job openings declined by 275,000 to 7.437 million in June, compared to market expectations of 7.55 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 2.8% year-over-year for May.</li>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $907.7 billion in June.</li>
<li>The U.S. trade deficit in goods shrank by $10.4 billion to $86 billion in June.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shuterstock

PFSA

US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings

DURECT Shares Halted On Circuit Breaker To The Downside, Stock Now Up 328.8%

DURECT Shares Resume Trade Following Circuit Breaker Halt

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation
Potential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitis
Proposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver disease complications globally
LAVAL, QC AND CUPERTINO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 29, 2025 / Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>)(TSX:<a class="ticker" href="https://www.benzinga.com/stock/BHC#TSX">BHC</a>), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) today announced a definitive agreement under which Bausch Health will indirectly acquire DURECT Corporation, including a novel therapeutic molecule, larsucosterol, which can harness the power of epigenetic modulation. Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for the treatment of alcoholic hepatitis (AH) in Phase 2 trials. Bausch Health's hepatology development and commercial capabilities are well-suited to support the clinical development and potential commercialization of larsucosterol.
AH is a life-threatening form of alcohol-associated liver disease (ALD), which can occur in individuals who chronically misuse alcohol. It is characterized by severe inflammation and destruction of liver tissue (i.e., necrosis). AH accounted for roughly 164,000 hospital admissions in the U.S. in 2021. There is currently no Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment for AH, and novel therapeutic strategies are needed to improve patient survival.
Transaction Terms and Financial Considerations Under the terms of the definitive agreement, a wholly owned subsidiary of Bausch Health will commence a tender offer for all outstanding shares of DURECT Corporation. Under the terms of the definitive agreement, Bausch Health will pay $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million at closing, with the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subject to certain adjustments in respect of a retention plan) if the milestone is achieved before the earlier of the 10 year anniversary of the first commercial sale in the United States and December 31, 2045. The purchase price payable at closing represents a premium of approximately 191% to the 30-day volume-weighted average trading price of DURECT's common stock ended on July 28, 2025, the last trading day before the announcement of the transaction. This upfront consideration represents a premium of approximately 217% to the trading price of DURECT's common stock ended on July 28, 2025.
The transaction is conditioned on a majority of the outstanding shares of DURECT Corporation's common stock being tendered into the tender offer and not withdrawn, as well as other customary closing conditions. The transaction is expected to close in the third quarter of 2025. Assuming the closing of the tender offer, Bausch Health will acquire any shares of DURECT not tendered into the tender offer through a merger of a wholly owned subsidiary with and into DURECT for the same per share consideration payable in the tender offer.

TSX:BHC

Reported Earlier: Bausch Health To Acquire DURECT And Its FDA Breakthrough Epigenetic Modulator Larsucosterol For Alcoholic Hepatitis In $63M Deal Plus Milestones

<h3>Gainers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares moved upwards by 270.9% to $2.05 during Tuesday's pre-market session. The company's market cap stands at $17.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 150.97% to $1.86. The company's market cap stands at $1.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock rose 50.14% to $0.83. The market value of their outstanding shares is at $18.9 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock increased by 42.43% to $2.92. The company's market cap stands at $1.9 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares rose 37.92% to $19.12. The market value of their outstanding shares is at $1.3 billion. </li>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock rose 27.54% to $108.3. The market value of their outstanding shares is at $2.4 billion. As per the news, the Q2 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) stock decreased by 39.6% to $4.35 during Tuesday's pre-market session. The company's market cap stands at $5.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 24.51% to $3.42. The company's market cap stands at $10.7 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock fell 20.96% to $54.54. The market value of their outstanding shares is at $306.5 billion. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) stock decreased by 15.5% to $6.6. The market value of their outstanding shares is at $421.5 million. As per the news, the Q2 earnings report came out today. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock fell 15.1% to $5.49. The market value of their outstanding shares is at $831.3 million. As per the press release, Q2 earnings came out today. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock decreased by 14.15% to $0.19. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FULC

SCNI

VTAK

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock rose 55.3% to $2.36 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares increased by 50.62% to $3.6. The company's market cap stands at $5.1 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 39.79% to $4.39. The market value of their outstanding shares is at $12.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 23.2% to $770.0. The company's market cap stands at $10.0 billion. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock moved upwards by 17.54% to $1.34. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock moved upwards by 14.12% to $1.45. The market value of their outstanding shares is at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock decreased by 29.8% to $21.5 during Friday's pre-market session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 22.37% to $1.18. The company's market cap stands at $121.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares fell 17.12% to $20.39. The company's market cap stands at $530.4 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 13.24% to $2.82. The company's market cap stands at $2.6 million. </li>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares fell 11.01% to $0.48. The market value of their outstanding shares is at $14.8 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 10.44% to $2.06. The company's market cap stands at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

ARAY

BJDX

EYEN

HSDT

LIMN

NIVF

VERA

VERO

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 45.0% to $1.74 during Friday's after-market session. The company's market cap stands at $23.9 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares moved upwards by 16.2% to $0.35. The company's market cap stands at $50.8 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock increased by 15.88% to $1.53. The market value of their outstanding shares is at $3.7 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock moved upwards by 9.24% to $10.75. The market value of their outstanding shares is at $2.0 billion. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 8.86% to $0.01. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 8.13% to $1.33. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares fell 11.4% to $0.57 during Friday's after-market session. The market value of their outstanding shares is at $17.7 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 8.83% to $6.55. The company's market cap stands at $352.3 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock decreased by 5.99% to $2.2. The company's market cap stands at $3.6 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares fell 5.85% to $1.45. The company's market cap stands at $47.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 5.16% to $4.05. The company's market cap stands at $2.4 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares fell 5.0% to $0.8. The company's market cap stands at $105.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

ENSC

ENVB

HCTI

NAOV

PEPG

PRTA

RAPT

SSII

SXTC

TIVC

12 Health Care Stocks Moving In Friday's After-Market Session

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 48 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $321.00 thousand which beat the analyst consensus estimate of $291.67 thousand by 10.06 percent. This is a 35.28 percent decrease over sales of $496.00 thousand the same period last year.

Earnings Beats

Earnings Misses

Durect Q1 EPS $(0.13) Misses $(0.12) Estimate, Sales $321.00K Beat $291.67K Estimate

HC Wainwright &amp; Co. analyst Ed Arce reiterates Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) from Neutral to Neutral.

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Durectto Neutral

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $(0.02) by 1300 percent. This is a 340 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $500.000 thousand which missed the analyst consensus estimate of $6.907 million by 92.76 percent. This is a 81.27 percent decrease over sales of $2.669 million the same period last year.

Durect Q4 2024 GAAP EPS $0.24 Beats $(0.02) Estimate, Sales $500.000K Miss $6.907M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is estimated to report quarterly loss at $5.00 per share on revenue of $5.60 million. 
• Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is projected to report quarterly earnings at $2.18 per share on revenue of $8.23 billion. 
• Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $3.20 billion. 
• Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $384.72 million. 
• Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.60 billion. 
• SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) is expected to report quarterly loss at $0.03 per share on revenue of $202.71 million. 
• REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $152.00 million. 
• CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $358 thousand. 
• Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $80.10 million. 
• JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) is estimated to report quarterly loss at $0.46 per share on revenue of $3.59 billion. 
• BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $1.35 billion. 
• Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $88.50 million. 
• Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is expected to report quarterly loss at $2.94 per share on revenue of $4.28 million. 
• Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) is expected to report earnings for its fourth quarter. 
• Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is projected to report quarterly earnings at $1.48 per share on revenue of $1.51 billion. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) is estimated to report earnings for its fourth quarter. 
• Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) is likely to report earnings for its fourth quarter. 
• TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) is likely to report earnings for its fourth quarter. 
• Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $40.63 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is projected to report quarterly loss at $0.11 per share on revenue of $114.96 million. 
• BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is projected to report quarterly loss at $0.87 per share on revenue of $20 thousand. 
• Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is projected to report earnings for its fourth quarter. 
• Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $6.91 million. 
• Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $14.21 million. 
• Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is expected to report earnings for its fourth quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $33.09 million. 
• Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is projected to report quarterly earnings at $1.13 per share on revenue of $1.97 billion. 
• Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $2.10 million. 
• H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $797.68 million. 
• Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is expected to report quarterly loss at $0.06 per share on revenue of $1.35 million. 
• Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $21.40 million. 
• Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $276.82 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $3.01 per share on revenue of $2.47 billion. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is projected to report earnings for its fourth quarter. 
• Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $790.90 million. 
• Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $320.52 million. 
• Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) is expected to report quarterly loss at $0.26 per share on revenue of $232 thousand. 
• MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $918.88 million. 
• Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $87.50 million. 
• Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $1.56 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

ALVO

BCDA

CATX

CHWY

CLGN

CMCM

CNXC

CTAS

DERM

DLTR

DOOO

DTIL

DYAI

GRDN

ITRG

MLKN

MVIS

OXBR

PAYX

SAIL

SNAL

Spruce Power Holding Corporation Class A Common Stock

SPRU

TATT

TTAM

USIO

VRNT

WOOF

ZEPP

Earnings Scheduled For March 26, 2025

DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET&#xAE; line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
<a href="https://mma.prnewswire.com/media/81466/DURECT_LOGO_2023.html">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (<a href="http://www.durect.com/">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer."&gt;
Under the terms of the agreement, LIC paid&nbsp;DURECT&nbsp;$17.5 million in exchange for certain assets and liabilities associated with&nbsp;the ALZET&nbsp;product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.&nbsp;

Asset Sales

DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations

HC Wainwright &amp; Co. analyst Ed Arce reiterates Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Durect

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. The company reported quarterly sales of $1.927 million which missed the analyst consensus estimate of $1.975 million by 2.43 percent. This is a 10.49 percent increase over sales of $1.744 million the same period last year.

Durect Q3 2024 GAAP EPS $(0.14) Beats $(0.17) Estimate, Sales $1.927M Miss $1.975M Estimate

Press Releases

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Small Cap

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders

DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders

Specificity Inc. (OTCID: SPTY) AI-Powered Technology Poised to Disrupt the Media Sector – More Stocks Inside

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NSC, SNV, DRRX, PNFP on Behalf of Shareholders

Comments

Durect

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL